We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 892

Life sciences & medical technology newsletter, Fall 2013 - Winter 2014
  • Greenberg Traurig LLP
  • USA
  • January 10 2014

On September 25, 2013, the U.S. Food and Drug Administration (the "FDA") released final guidance on the regulatory requirements regarding the


Control at issue in split Federal Circuit ruling on joint infringement
  • Shook Hardy & Bacon LLP
  • USA
  • April 21 2011

A divided Federal Circuit Court of Appeals panel, relying on recent precedent, has confirmed that "where the actions of multiple parties combine to perform every step of a claimed method, the claim is directly infringed only if one party exercises 'control or direction' over the entire process such that every step is attributable to the controlling party."


CAFC weekly: November 5, 2010
  • Burns & Levinson LLP
  • USA
  • November 10 2010

After two weeks of not handing down precedential opinions, this week the CAFC provided us with a split decision on denial of en banc review, an opinion affirming a grant of a preliminary injunction, as well as an opinion presenting an example of the usefulness of "Beauregard" claims, which are claims in which software is claimed by claiming the storage medium having the computer code embodied therein


Patenting business methods after Mayo
  • Foley & Lardner LLP
  • USA
  • July 30 2012

Advances in information technology, such as high-performance computing, enables the collection, analysis and sharing of information between patients and medical providers


Noteworthy cases in the United States Supreme Court’s 2011 term
  • Larkin Hoffman
  • USA
  • September 21 2011

The first Monday in October represents the start of a new term for the United States Supreme Court


Evaluating life sciences inventions: surveying patents similar to assessing real estate
  • Pillsbury Winthrop Shaw Pittman LLP
  • USA
  • March 29 2011

Pillsbury Life Sciences team co-head Dr. John Wetherell explains why evaluating the worth of intangible IP in this sector is not all that different from assessing the value of real property


Copyright for Engineered DNA (Part 2)
  • GQ Life Sciences
  • USA
  • March 1 2016

With the United States Supreme Court ruling in Myriad, the enforceability of certain claims in existing gene patents and the broader patentability of


Precision Medicine Initiative moves forward with new guidelines and funding opportunities
  • Hogan Lovells
  • USA
  • December 2 2015

The White House released the Precision Medicine Initiative (PMI) Privacy and Trust Principles, aimed at building patient trust and protecting patient


Copyright for Engineered DNA
  • GQ Life Sciences
  • USA
  • February 23 2016

With the United States Supreme Court ruling in Myriad,the enforceability of certain claims in existing gene patents and the broader patentability of


Expect focus - volume III, Summer 2014
  • Carlton Fields
  • USA
  • September 16 2014

EXPECTFOCUS is a quarterly review of developments in the insurance and financial services industry, provided on a complimentary basis to clients and